Growing demand for safe, effective medicines for pulmonary disorders and diseases has increased the research into their treatment. This is key to discovering how to effectively manage pathological lung conditions including asthma, chronic obstructive pulmonary disease (COPD), pneumonia and lung cancer. Nicolau Beckmann at Novartis Institutes and Sarah Rebecca Herrmann at Bruker BioSpin show the developments in non-invasive pre-clinical lung imaging to support drug discovery.